Optimization of therapy in secondary progressive multiple sclerosis
https://doi.org/10.14412/2074-2711-2024-2S-88-90
Abstract
The article provides an analysis of modern methods of treatment of secondary progressive multiple sclerosis (SPMS). The only drug that has proven its effectiveness in all types of SPMS (with exacerbations and without exacerbations) is siponimod. Clinical trials of this drug have proven its efficacy and safety in this type of MS. If the drug is included in the list of high-cost technologies, this modern method of treating SPMS can be made available to all patients who need it.
Supporting agencies: The article is sponsored by Novartis
About the Authors
A. N. Boyko
N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia; Federal Center of Brain and Neurotechnologies, FMBA of Russia
Russian Federation
Competing Interests:
Russian Federation
Alexey Nikolaevich Boyko
1, Ostrovityanova St., Moscow 117997; 1, Ostrovityanova St., Build. 10, Moscow 117997
Competing Interests:
The conflict of interests did not affect the results of the study
S. K. Zyryanov
Peoples' Friendship University of Russia named after Patrice Lumumba (RUDN University); City Clinical Hospital No. 24, Moscow City Healthcare Department
Russian Federation
Competing Interests:
Russian Federation
6, Miklukho-Maklaya St., Moscow 117198; 10, Pistsovaya St., Moscow 127015
Competing Interests:
The conflict of interests did not affect the results of the study
Ya. V. Vlasov
Samara State Medical University, Ministry of Health of Russia
Russian Federation
Competing Interests:
Russian Federation
89, Chapaevskaya St., Samara 443099
Competing Interests:
The conflict of interests did not affect the results of the study
References
1. Giovannoni G, Butzkueven H, Dhib-Jalbut S, et al. Brain health: time matters in multiple sclerosis. Mult Scler Relat Disord. 2016 Sep;9 Suppl 1:S5-S48. doi: 10.1016/j.msard.2016.07.003. Epub 2016 Jul 7.
2. Boyko A, Melnikov M. Prevalence and Incidence of Multiple Sclerosis in Russian Federation: 30 Years of Studies. Brain Sci. 2020 May 18;10(5):305. doi: 10.3390/brainsci10050305
3. Koch-Henriksen N, Magyari M. Apparent changes in the epidemiology and severity of multiple sclerosis. Nat Rev Neurol. 2021 Nov;17(11):676-88. doi: 10.1038/s41582-021-00556-y. Epub 2021 Sep 28.
4. Lublin FD, Reingold SC, Cohen JA, et al. Defining the clinical course of multiple sclerosis: the 2013 revisions. Neurology. 2014 Jul 15;83(3):278-86. doi: 10.1212/WNL.0000000000000560. Epub 2014 May 28.
5. Власов ЯВ, Чураков МВ, Курапов МА и др. Первично-прогрессирующий рассеянный склероз в России: медико-социологическое исследование с участием пациентов и неврологов. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2018;118(8-2):40-6. doi: 10.17116/jnevro201811808240
6. Pozzilli C, Pugliatti M, Vermersch P, et al. Diagnosis and treatment of progressive multiple sclerosis: A position paper. Eur J Neurol. 2023 Jan;30(1):9-21. doi: 10.1111/ene.15593. Epub 2022 Oct 25.
7. Krieger SC, Sumowski J. New Insights into Multiple Sclerosis Clinical Course from the Topographical Model and Functional Reserve. Neurol Clin. 2018 Feb;36(1):13-25. doi: 10.1016/j.ncl.2017.08.003. Epub 2017 Oct 18.
8. Kapoor R, Ho PR, Campbell N, et al; ASCEND investigators. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018 May;17(5):405-15. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12.
9. Kappos L, Weinshenker B, Pozzilli C, et al; European (EU-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta-1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board. Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004 Nov 23;63(10):1779-87. doi: 10.1212/01.wnl.0000145561.08973.4f
10. Kappos L, Bar-Or A, Cree BAC, et al; EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study. Lancet. 2018 Mar 31;391(10127):1263-73. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170. doi: 10.1016/S0140-6736(18)32834-4
11. Glaenzel U, Jin Y, Nufer R, et al. Metabolism and Disposition of Siponimod, a Novel Selective S1P1/S1P5 Agonist, in Healthy Volunteers and In Vitro Identification of Human Cytochrome P450 Enzymes Involved in Its Oxidative Metabolism. Drug Metab Dispos. 2018 Jul;46(7):1001-13. doi: 10.1124/dmd.117.079574. Epub 2018 May 7.
12. Diaz-Villamarin X, Pinar-Morales R, Barrero-Hernandez FJ, et al. Pharmacogenetics of siponimod: A systematic review. Biomed Pharmacother. 2022;153:113536. doi: 10.1016/j.biopha.2022
13. Касаткин ДС, Хачанова НВ, Алифирова ВМ и др. Новые возможности терапии у пациентов с вторично-прогрессирующим рассеянным склерозом препаратом сипонимод. Неврология, нейропсихиатрия, психосоматика. 2021;13(1):138-44. doi: 10.14412/2074-2711-2021-1-138-144
14. O'Sullivan C, Schubart A, Mir AK, Dev KK. The dual S1PR1/S1PR5 drug BAF312 (Siponimod) attenuates demyelination in organotypic slice cultures. J Neuroinflammation. 2016 Feb 8;13:31. doi: 10.1186/s12974-016-0494-x
15. Евдошенко ЕП, Неофидов НА, Бахтиярова КЗ и др. Эффективность и безопасность сипонимода в российской популяции пациентов с вторично-прогрессирующим рассеянным склерозом. Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2019;119(10-2):110-9. doi: 10.17116/jnevro201911910110
16. Протокол заседания Комиссии МЗ РФ от 04.08.2022. Доступно по ссылке: https://minzdrav.gov.ru/ministry/61/10/stranitsa-858/stranitsa-7375
Review
For citations:
Boyko AN, Zyryanov SK, Vlasov YV. Optimization of therapy in secondary progressive multiple sclerosis. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2024;16:88-90. (In Russ.) https://doi.org/10.14412/2074-2711-2024-2S-88-90
Views:
226
Email this article 